PSNL Key Statistics, Chart & Performance
The current stock price of PSNL is 7.85 USD. In the past month the price decreased by -22.81%. In the past year, price increased by 18.22%.
PSNL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.45 | 222.61B | ||
| DHR | DANAHER CORP | 29.88 | 162.74B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 184.77 | 56.15B | ||
| A | AGILENT TECHNOLOGIES INC | 24.72 | 39.11B | ||
| IQV | IQVIA HOLDINGS INC | 19.38 | 38.38B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.73 | 28.83B | ||
| WAT | WATERS CORP | 30.08 | 22.74B | ||
| ILMN | ILLUMINA INC | 30.81 | 20.53B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.09 | 19.88B | ||
| MEDP | MEDPACE HOLDINGS INC | 39.93 | 16.09B | ||
| RVTY | REVVITY INC | 20.49 | 11.13B | ||
| TEM | TEMPUS AI INC | N/A | 11.09B |
Related stock screener links
About PSNL
Company Profile
Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The company is headquartered in Fremont, California and currently employs 229 full-time employees. The company went IPO on 2019-06-20. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The firm performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Company Info
PERSONALIS INC
6600 Dumbarton Circle
Fremont CALIFORNIA 94025 US
CEO: John West
Employees: 229
Phone: 16507521300
PERSONALIS INC / PSNL FAQ
Can you describe the business of PERSONALIS INC?
Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The company is headquartered in Fremont, California and currently employs 229 full-time employees. The company went IPO on 2019-06-20. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The firm performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Can you provide the latest stock price for PERSONALIS INC?
The current stock price of PSNL is 7.85 USD. The price decreased by -1.38% in the last trading session.
Does PSNL stock pay dividends?
PSNL does not pay a dividend.
How is the ChartMill rating for PERSONALIS INC?
PSNL has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of PERSONALIS INC (PSNL)?
PERSONALIS INC (PSNL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.88).
What is the market capitalization of PSNL stock?
PERSONALIS INC (PSNL) has a market capitalization of 697.08M USD. This makes PSNL a Small Cap stock.
What is the ownership structure of PERSONALIS INC (PSNL)?
You can find the ownership structure of PERSONALIS INC (PSNL) on the Ownership tab.
PSNL Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PSNL. When comparing the yearly performance of all stocks, PSNL is one of the better performing stocks in the market, outperforming 77.33% of all stocks.
PSNL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PSNL. PSNL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PSNL Financial Highlights
Over the last trailing twelve months PSNL reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 47.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.42% | ||
| ROE | -43.1% | ||
| Debt/Equity | 0 |
PSNL Forecast & Estimates
13 analysts have analysed PSNL and the average price target is 11.22 USD. This implies a price increase of 42.93% is expected in the next year compared to the current price of 7.85.
For the next year, analysts expect an EPS growth of 29.7% and a revenue growth -16.36% for PSNL